Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.51 |
| ▸ | PYGB | P11216 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15444965 | 1.00 | LGALS8 (0.51) | LGALS8PYGBGAAL3MBTL1MAPT | |
| SCHEMBL8591368 | 1.00 | LGALS8 (0.51) | LGALS8PYGBGAAL3MBTL1MAPT | |
| SCHEMBL8591360 | 1.00 | LGALS8 (0.51) | LGALS8PYGBGAAL3MBTL1MAPT | |
| SCHEMBL3268722 | 1.00 | LGALS8 (0.51) | LGALS8PYGBGAAL3MBTL1MAPT | |
| SCHEMBL8811814 | 0.86 | IGF2R (0.44) | LGALS8 | |
| SCHEMBL8811807 | 0.86 | IGF2R (0.44) | LGALS8 | |
| SCHEMBL12500139 | 0.84 | LGALS8 (0.49) | LGALS8PYGBGAALGALS3 | |
| SCHEMBL15316747 | 0.84 | LGALS8 (0.49) | LGALS8PYGBGAALGALS3 | |
| SCHEMBL17274485 | 0.81 | GAA (0.51) | LGALS8GAAL3MBTL1MAPTLGALS3 | |
| SCHEMBL1450206 | 0.81 | GAA (0.51) | LGALS8GAAL3MBTL1MAPTLGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2008007153-A2 | ANTIVIRAL COMPOUNDS | IQUR LTD. (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | LGALS8 879/4885PYGB 3381/4885GAA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.